Modulation of vascular smooth muscle cell phenotype by STAT-1 and STAT-3

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 169-175

  Kirchmer, Mayumi Namekata ^a   Franco, Anais ^a,b   Albasanz Puig, Adaia ^a,c   Murray, Jacqueline ^a   Yagi, Mayumi ^a   Gao, Lu ^a   Dong, Zhao Ming ^a   Wijelath, Errol S ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Oncostatin M; Phenotype; Smooth muscle cell; STAT 1; STAT 3

Indexed keywords

CALPONIN; SHORT HAIRPIN RNA; STAT1 PROTEIN; STAT3 PROTEIN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; BIOINFORMATICS; CELL DEDIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; PHYSIOLOGY;

CELL DEDIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84897930793     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.029     Document Type: Article

References (35)

1. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:812-819.
2. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
3. Regan C.P., Adam P.J., Madsen C.S., Owens G.K. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. JClin Invest 2000, 106:1139-1147.
4. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2045-2051.
5. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
6. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. JBiol Chem 2007, 282:20059-20063.
7. Grote K., Luchtefeld M., Schieffer B. JANUS under stress - role of JAK/STAT signaling pathway in vascular diseases. Vasc Pharmacol 2005, 43:357-363.
8. Demyanets S., Huber K., Wojta J. Vascular effects of glycoprotein130 ligands - part I: pathophysiological role. Vasc Pharmacol 2012, 56:34-46.
9. Hou T., Tieu B.C., Ray S., et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008, 4:179-192.
10. Albasanz-Puig A., Murray J., Preusch M., et al. Oncostatin M is expressed in atherosclerotic lesions: a role for oncostatin M in the pathogenesis of atherosclerosis. Atherosclerosis 2011, 216:292-298.
11. Demyanets S., Kaun C., Rychli K., et al. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-gamma. Basic Res Cardiol 2011, 106:217-231.
12. Rose T.M., Bruce A.G. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci U S A 1991, 88:8641-8645.
13. Langdon C., Leith J., Smith F., Richards C.D. Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts invitro. Arthritis Rheum 1997, 40:2139-2146.
14. Nishibe T., Parry G., Ishida A., et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. Blood 2001, 97:692-699.
15. Modur V., Feldhaus M.J., Weyrich A.S., et al. Oncostatin M is a proinflammatory mediator. Invivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. JClin Invest 1997, 100:158-168.
16. Kastl S.P., Speidl W.S., Katsaros K.M., et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 2009, 114:2812-2818.
17. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
18. Nowak D.E., Tian B., Brasier A.R. Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques 2005, 39:715-725.
19. Long X., Slivano O.J., Cowan S.L., Georger M.A., Lee T.H., Miano J.M. Smooth muscle calponin: an unconventional CArG-dependent gene that antagonizes neointimal formation. Arterioscler Thromb Vasc Biol 2011, 31:2172-2180.
20. Miano J.M., Carlson M.J., Spencer J.A., Misra R.P. Serum response factor-dependent regulation of the smooth muscle calponin gene. JBiol Chem 2000, 275:9814-9822.
21. Rajotte D., Sadowski H.B., Haman A., et al. Contribution of both STAT and SRF/TCF to c-fos promoter activation by granulocyte-macrophage colony-stimulating factor. Blood 1996, 88:2906-2916.
22. Yang E., Lerner L., Besser D., Darnell J.E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. JBiol Chem 2003, 278:15794-15799.
23. Di Taranto M.D., Morgante A., Bracale U.M., et al. Altered expression of inflammation-related genes in human carotid atherosclerotic plaques. Atherosclerosis 2012, 220:93-101.
24. Albasanz-Puig A., Murray J., Namekata M., Wijelath E.S. Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 428:179-184.
25. Regis G., Pensa S., Boselli D., Novelli F., Poli V. Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008, 19:351-359.
26. Torella D., Curcio A., Gasparri C., et al. Fludarabine prevents smooth muscle proliferation invitro and neointimal hyperplasia invivo through specific inhibition of STAT-1 activation. Am J Physiol Heart Circ Physiol 2007, 292:H2935-H2943.
27. Daniel J.M., Dutzmann J., Bielenberg W., et al. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 2012, 107:261.
28. Yue H., Tanaka K., Furukawa T., Karnik S.S., Li W. Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3. Biochim Biophys Acta 2012, 1823:1316-1323.
29. Wang D.Z., Li S., Hockemeyer D., et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci U S A 2002, 99:14855-14860.
30. Wang Z., Wang D.Z., Hockemeyer D., McAnally J., Nordheim A., Olson E.N. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 2004, 428:185-189.
31. Mack C.P. Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011, 31:1495-1505.
32. Gomez D., Owens G.K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012, 95:156-164.
33. Liu Y., Sinha S., McDonald O.G., Shang Y., Hoofnagle M.H., Owens G.K. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. JBiol Chem 2005, 280:9719-9727.
34. Yoshida T., Gan Q., Shang Y., Owens G.K. Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. Am J Physiol Cell Physiol 2007, 292:C886-C895.
35. Deaton R.A., Gan Q., Owens G.K. Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle. Am J Physiol Heart Circ Physiol 2009, 296:H1027-H1037.